TSLA
Tesla
-- 431.660 RGTI
Rigetti Computing
-- 17.0800 NVDA
NVIDIA
-- 137.010 INTC
Intel
-- 20.300 NIO
NIO Inc
-- 4.480 
ADDED NEWS
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics (Nasdaq: GLUE) has closed its global exclusive development and commercialization license agreement with Novartis for VAV1-directed molecular glue degraders (MGDs), including MRT-6160. The deal includes a $150 million upfront paymentand potential earnings of up to $2.1 billion in development, regulatory, and sales milestones. Novartis gains worldwide rights and will handle clinical development and commercialization from Phase 2 onwards, while Monte Rosa completes the ongoing Phase 1 study.
Monte Rosa will co-fund Phase 3 development and share U.S. profits and losses, receiving tiered royalties on ex-U.S. sales. MRT-6160 is an oral VAV1 degrader showing promise in preclinical studies for immune-mediated conditions.
Monte Rosa will co-fund Phase 3 development and share U.S. profits and losses, receiving tiered royalties on ex-U.S. sales. MRT-6160 is an oral VAV1 degrader showing promise in preclinical studies for immune-mediated conditions.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment